Skip to content
ppharmaranks
Menu
CompaniesProductsDrug classesConditionsBest by conditionTreatmentsInteraction checkerFood & medicinesWhat pharmacies payPill identifierMedicines & breastfeedingChildren’s dosage chartsDo medicines expire?Crushing & splitting pillsHow long meds take to workAlternating Tylenol & ibuprofenDrug recallsSupplementsSafety & lawsuitsGuidesA–ZHow we rate

Platelet-reducing Agent drugs compared

Compare all 2 Platelet-reducing Agent drugs side by side, used for conditions such as polycythemia vera, thrombocytosis. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.

Full ranking · 2 drugs

  1. 1

    anagrelide hydrochloride

    Anagrelide Hydrochloride

    70/100
  2. 2

    agrylin

    Anagrelide Hydrochloride

    New

Frequently asked questions

What is the Platelet-reducing Agent drug class?

Platelet-reducing Agent is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 2 Platelet-reducing Agent products, each independently rated.

Are all Platelet-reducing Agent drugs the same?

No. Platelet-reducing Agent drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do Platelet-reducing Agent drugs treat?

Per NIH RxClass drug-classification data, Platelet-reducing Agent drugs are used for conditions including polycythemia vera, thrombocytosis.

Sources: the Platelet-reducing Agent class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.